Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia
about
Nonmyeloablative allogeneic hematopoietic cell transplantationNovel agents and biomarkers for acute lymphoid leukemiaImatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cellsAllogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis.Marrow damage and hematopoietic recovery following allogeneic bone marrow transplantation for acute leukemias: Effect of radiation dose and conditioning regimen.Conditioning regimens for hematopoietic cell transplantation: one size does not fit allRole of allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia.Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial.Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adultsCellular therapies in acute lymphoblastic leukemiaGraft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantationUKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.The role of allogeneic hematopoietic stem cell transplantation in the therapy of patients with acute lymphoblastic leukemia.Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools.Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia.Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission.Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission.Current and future management of Ph/BCR-ABL positive ALL.Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment.Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia.Allogeneic stem cell transplantation for adult acute lymphoblastic leukemia: when and how.Adult acute lymphoblastic leukaemia in Denmark. A national population-based retrospective study on acute lymphoblastic leukaemia in Denmark 1998-2008.Treatment of Older Patients with Acute Lymphoblastic Leukaemia.Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT.Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission.Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working pa
P2860
Q26748780-1E85E062-F844-401B-B8CD-8D0E7144C962Q26829775-F32A977F-1FF1-4B3F-9F72-B31761EF25CDQ28484493-4F69C52A-60D0-43FC-A1C4-52B4136D5813Q30577948-643E0A60-8F53-4EE8-A9CC-F9CF1397F667Q33428284-CFB63C0C-F2E0-43DB-8FBD-2C5261FDD325Q33917170-DBD8BCEA-8FEF-490F-9D2E-359948F2FDECQ34532041-D310DD0D-D67E-4424-A4EF-1C4EBB074200Q35146312-2343D834-86B7-43A0-844D-CEE33399BBA5Q35731623-7255AC66-FB95-4561-9B1E-DD5F9A7B4C06Q36036328-B85EDC60-92E7-4CF6-B457-51376E45C335Q36461915-25A57373-4AA0-4C51-A5E7-9EF9883F9F88Q36552098-9E063536-B6E6-4CA3-89A1-3972397B264CQ36763834-5A12F5ED-C9D3-4FFC-8D21-C26402F433AFQ37564762-30B7387C-7767-4619-9AF8-CB9B413286EDQ37632798-403C7AF4-0E31-4F14-80CD-3BDD591CEE18Q37992837-70CCD30D-51EE-42DC-8BB0-1C69A91745C1Q38023947-34C2779E-F62A-4CC8-B681-7EB0EA4B3DDEQ38028808-9AF8C2CF-4A52-4574-8CFA-FA7CA5041E0BQ38079288-14E2EDFC-C92E-4D9A-9D32-B45E244DF64DQ38087930-C18130D7-24B3-4F86-B787-475A66520DD5Q38098957-44DA9C89-FA01-4693-B7DD-470D5787D723Q38133244-CD3B6323-EBAB-4AA1-A518-6D5A67DB7411Q38194585-FC892C15-05C3-435D-BB06-6CE68F60246BQ38226100-1E258020-C38C-4DF6-BDD2-3F6EE69083D3Q38488058-B270C93F-BAEB-4552-A389-580CB9D75741Q38829019-05207BC1-99ED-4303-B12F-1ED5106E4D31Q41009415-725AEE9C-5209-4D0F-84B5-AE02E2A27C84Q42852351-F35F0A00-C5EC-435F-AE7F-E2EC8F775BB5Q43833498-225F6731-10DB-4929-B4A9-10B4832B1246Q47774455-42E687F4-FC88-42E6-BCE7-7571C07A8139Q49165760-65F3A02C-2234-47B7-BADB-0EC531AA6C13Q51815713-A68C6A8D-4F6C-4912-8C04-FB361E238056Q55073539-6642F42C-88AD-4ABA-A9E9-548EEDE54C44
P2860
Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Non-myeloablative conditioning ...... k acute lymphoblastic leukemia
@ast
Non-myeloablative conditioning ...... k acute lymphoblastic leukemia
@en
type
label
Non-myeloablative conditioning ...... k acute lymphoblastic leukemia
@ast
Non-myeloablative conditioning ...... k acute lymphoblastic leukemia
@en
prefLabel
Non-myeloablative conditioning ...... k acute lymphoblastic leukemia
@ast
Non-myeloablative conditioning ...... k acute lymphoblastic leukemia
@en
P2093
P2860
P50
P1433
P1476
Non-myeloablative conditioning ...... k acute lymphoblastic leukemia
@en
P2093
Amelia A Langston
Ann Woolfrey
George E Georges
Ginna G Laport
Mary E D Flowers
Michael B Maris
Thoralf Lange
P2860
P304
P356
10.3324/HAEMATOL.2011.040261
P577
2011-04-20T00:00:00Z